Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Immunome, Inc.

< Previous 1 2 3 Next >
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Second Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports First Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present at 13th Annual World ADC London Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
From Immunome, Inc.
Via Business Wire
Tickers IMNM
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
From Immunome, Inc.
Via Business Wire
Tickers ABBV IMNM
Immunome Reports Third Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Second Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present at the Jefferies Healthcare Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports First Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Third Quarter 2021 Financial Results
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present at the Stifel Healthcare Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immunome, Inc.
Via Business Wire
Tickers IMNM
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.